Source: Autobound Signal API · 102 signals tracked for Eli Lilly · updated
Get Eli Lilly's live signals in Claude or ChatGPT, or by API
What changed at Eli Lilly this week? Use Autobound signals for lilly.com.Eli Lilly completed the acquisition of AtaiBeckley in Q3 2026 to advance mental health therapies and subsequently closed its acquisition of Merida Biosciences.
Filing excerpt
Business development activity in Q3 2026 included the completed acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. Subsequent to quarter end, we completed the acquisition of Merida Biosciences, to advance treatments for serious autoimmune and allergic diseases.
What this signalsIntegration work after a deal often opens needs for new systems and services.
sec-8kacquisitionCompletedGet every 8-K signal for Eli Lilly and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/25430522-85b7-4fee-b2ba-73cc954ea789 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.
{
"signal_id": "25430522-85b7-4fee-b2ba-73cc954ea789",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-11-03T07:18:18.432+00:00",
"company": {
"name": "Eli Lilly",
"domain": "lilly.com"
},
"data": {
"detail": "Eli Lilly completed the acquisition of AtaiBeckley in Q3 2026 to advance mental health therapies and subsequently closed its acquisition of Merida Biosciences. Sellers of clinical trial management, lab informatics, and integration consulting may find near-term opportunities.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "acquired IPR&D charges primarily related to acquisitions of AtaiBeckley and Curevo"
},
"summary": "Eli Lilly completes acquisition of AtaiBeckley and subsequently acquires Merida Biosciences",
"excerpts": "Business development activity in Q3 2026 included the completed acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. Subsequent to quarter end, we completed the acquisition of Merida Biosciences, to advance treatments for serious autoimmune and allergic diseases.",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/lly-20261029.htm",
"filing_date": "2026-10-29",
"filing_year": 2026,
"fiscal_year_end": "10/29",
"sales_relevance": "Active integration needs",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/25430522-85b7-4fee-b2ba-73cc954ea789 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.